rs28936684
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 15P and 1B. PM1PM2PM5PP2PP5_Very_StrongBP4
The NM_000388.4(CASR):c.680G>A(p.Arg227Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00000137 in 1,461,866 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R227L) has been classified as Pathogenic.
Frequency
Consequence
NM_000388.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CASR | NM_000388.4 | c.680G>A | p.Arg227Gln | missense_variant | 4/7 | ENST00000639785.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CASR | ENST00000639785.2 | c.680G>A | p.Arg227Gln | missense_variant | 4/7 | 1 | NM_000388.4 | P1 | |
CASR | ENST00000498619.4 | c.680G>A | p.Arg227Gln | missense_variant | 4/7 | 1 | |||
CASR | ENST00000638421.1 | c.680G>A | p.Arg227Gln | missense_variant | 4/7 | 5 | P1 | ||
CASR | ENST00000490131.7 | c.680G>A | p.Arg227Gln | missense_variant | 3/5 | 5 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 250970Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135608
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461866Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 727228
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Nephrolithiasis/nephrocalcinosis Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 08, 2023 | The p.R227Q variant (also known as c.680G>A), located in coding exon 3 of the CASR gene, results from a G to A substitution at nucleotide position 680. The arginine at codon 227 is replaced by glutamine, an amino acid with highly similar properties. This variant has been detected in two unrelated families with familial hypocalciuric hypercalcemia and segregated with affected individuals in these families (Chou YH et al. Am J Hum Genet, 1995 May;56:1075-9; Wystrychowski A et al. J Clin Endocrinol Metab, 2005 Feb;90:864-70). In vitro functional studies showed that cells expressing R227Q have decreased sensitivity to extracellular calcium concentrations (Wystrychowski A et al. J Clin Endocrinol Metab, 2005 Feb;90:864-70; Lu JY et al. J Pharmacol Exp Ther, 2009 Dec;331:775-86; Grant MP et al. Mol Endocrinol, 2012 Dec;26:2081-91; Glaudo M et al. Eur J Endocrinol, 2016 Nov;175:421-31). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
CASR-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 02, 2023 | The CASR c.680G>A variant is predicted to result in the amino acid substitution p.Arg227Gln. This variant has been reported in multiple individuals with familial hypocalciuric hypocalcemia (FHH) (Chou et al. 1995. PubMed ID: 7726161; Wystrychowski et al. 2005. PubMed ID: 15572418; Hannan et al. 2012. PubMed ID: 22422767; Vargas-Poussou et al. 2016. PubMed ID: 26963950). Additionally, several in vitro experimental studies have demonstrated that CASR protein carrying the p.Arg227Gln variant has impaired sensitivity to elevated extracellular calcium levels relative to wild type (Wystrychowski et al. 2005. PubMed ID: 15572418; White et al. 2009. PubMed ID: 19389809; Grant et al. 2012. PubMed ID: 23077345; Glaudo et al. 2016. PubMed ID: 27666534). This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/3-121980562-G-A). Alternate nucleotide changes affecting the same amino acid (p.Arg227Leu, p.Arg227Gly) have also been reported as pathogenic in individuals with CASR-associated disease (Pearce et al. 1995. PubMed ID: 8675635; Glaudo et al. 2016. PubMed ID: 27666534). Taken together, the p.Arg227Gln variant is interpreted as pathogenic. - |
Familial hypocalciuric hypercalcemia 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 1995 | - - |
Autosomal dominant hypocalcemia 1;C1809471:Familial hypocalciuric hypercalcemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 227 of the CASR protein (p.Arg227Gln). This variant is present in population databases (rs28936684, gnomAD 0.0009%). This missense change has been observed in individual(s) with familial hypocalciuric hypercalcemia (FHH) (PMID: 1302026, 7726161, 15572418, 22422767, 26963950). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 8331). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects CASR function (PMID: 19389809, 19759318, 23077345, 27666534). For these reasons, this variant has been classified as Pathogenic. - |
Autosomal dominant hypocalcemia 1;C0342637:Familial hypocalciuric hypercalcemia 1;C1832615:Neonatal severe primary hyperparathyroidism;C2752062:Epilepsy, idiopathic generalized, susceptibility to, 8 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 09, 2021 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | May 03, 2017 | - - |
Familial hypocalciuric hypercalcemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 24, 2022 | Variant summary: CASR c.680G>A (p.Arg227Gln) results in a conservative amino acid change in the encoded protein sequence. Two of four in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251070 control chromosomes (gnomAD and publication data). c.680G>A has been reported in the literature in multiple individuals affected with Familial Hypocalciuric Hypercalcemia (Chou_1992, Wystrychowski_2005, Glaudo_2016). These data indicate that the variant is very likely to be associated with disease. Functional studies report experimental evidence evaluating an impact on protein function and results in reducing ability to induce ERK1/2 phosphorylation (Wystrychowski_2005, White_2009, Glaudo_2016). Two ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at